Level of virulent virus excreted by infected pigs previously vaccinated with different glycoprotein deleted Aujeszky's disease vaccines.
Seven deleted Aujeszky's disease vaccines were compared for their ability to induce an immunity which suppresses virus excretion. For each vaccine, the levels of clinical protection and viral excretion were compared. Groups of eight pigs were vaccinated twice with attenuated deleted Aujeszky's disease vaccines (which do not express certain glycoproteins: gI, gX or gp63). Pigs were vaccinated at the beginning of the fattening period and challenge took place at the end of it when the pigs were 18-19 weeks old. Live virus vaccines were suspended in water or in an oil-in-water emulsion. The experiment was performed in three successive assays of two groups of eight pigs (except three groups for the first assay). At each assay, a control unvaccinated group of eight pigs was added to compare the effects of challenge between vaccinated and unvaccinated animals. In total, 80 pigs were involved in this experiment. All the vaccinated pigs excreted virus from 3 to 9 d after challenge. However the level of viral excretion and the duration of the period of excretion were reduced after vaccination and especially, when oil-in-water emulsion was used. There were obvious differences between vaccines. With some vaccines, when the level of viral excretion was low, the level of clinical protection was high. However, in other cases, the level of clinical protection could be good despite a higher level of viral excretion. The seroneutralizing titres were significantly and inversely related to a low level of viral excretion but not to the level of clinical protection.
Vannier
P
P
CNEVA, Laboratoire Central de Recherches Avicole, Ploufragan, France.
Hutet
E
E
Bourgueil
E
E
Cariolet
R
R
D000818:Animals; D011558:Herpesvirus 1, Suid / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity; D007117:Immunization, Secondary; D007273:Injections, Intramuscular / Q000662:veterinary; D009297:Nasal Mucosa / Q000382:microbiology; D011557:Pseudorabies / Q000382:microbiology / Q000517:prevention & control*; D013552:Swine; D014611:Vaccination / Q000662:veterinary*; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage; D014774:Virulence
D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C042966:pseudorabies virus glycoproteins